Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 84Recurrence 10Lymphoma 8Leukemia, Myeloid, Acute 6Immunoglobulin Light-chain Amyloidosis 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma, Mantle-Cell 5Waldenstrom Macroglobulinemia 4Neoplasms, Plasma Cell 3Hematologic Neoplasms 3Plasmacytoma 2Neoplasms 2Lymphoma, T-Cell, Peripheral 2Lymphoma, Follicular 2Lymphoma, B-Cell 2Leukemia, Plasma Cell 2Leukemia, Biphenotypic, Acute 2Carcinoma, Renal Cell 2Breast Neoplasms 2Amyloidosis 2Triple Negative Breast Neoplasms 1Smoldering Multiple Myeloma 1Sarcoma, Kaposi 1Sarcoma, Ewing 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Proteostasis Deficiencies 1Plasmablastic Lymphoma 1POEMS Syndrome 1Neurofibrosarcoma 1

Interventions

Cyclophosphamide 20Brentuximab Vedotin 20fludarabine 16Lenalidomide 13Rituximab 12Dexamethasone 12fludarabine phosphate 10Melphalan 10Busulfan 10Mycophenolic Acid 9dacetuzumab 7Whole-Body Irradiation 7Tacrolimus 7pirtobrutinib 6Doxorubicin 6Bortezomib 6Azacitidine 6ruxolitinib 5Vincristine 5Prednisone 5Imatinib Mesylate 5ponatinib 4pomalidomide 4Mesna 4Granulocyte Colony-Stimulating Factor 4Etoposide 4Bone Marrow Transplantation 4Bendamustine Hydrochloride 4venetoclax 3nilotinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Hematologic Diseases × ixazomib × Clear all
NCT02440464 2023-01-04

Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)

National Heart, Lung, and Blood Institute (NHLBI)

Phase 2 Completed
57 enrolled 22 charts
Plasma cell

Hematologic Diseases, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡